Cambria Pharmaceuticals Reaps $5.4M Financing

Cambria Pharmaceuticals of Woburn, MA, has received $5.4 in a Series A round joined by Biogen Idec New Ventures, CommonAngels, and several individual investors, the company announced today. Cambria aims to find new treatments for neurological disorders, especially ALS, also known as Lou Gehrig’s disease.

Author: Erik Mellgren

Erik Mellgren is a Swedish journalist who worked for Xconomy Boston in 2008 as part of the Stanford Innovation Journalism Fellowship program. He is a 26-year veteran of Ny Teknik, a leading technology and innovation magazine in Sweden. View all posts by Erik Mellgren